Xeris Pharmaceuticals Inc Cash Flow Conversion Efficiency
Xeris Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Xeris Pharmaceuticals Inc (XERS) has a cash flow conversion efficiency ratio of -0.849x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.26 Million) by net assets ($-9.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Xeris Pharmaceuticals Inc (2016–2025)
Cash flow conversion efficiency of Xeris Pharmaceuticals Inc from 2016 to 2025. This chart illustrates how Xeris Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XERS stock price and chart for real-time trading data and today's change.
Xeris Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Xeris Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Xeris Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xeris Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see market cap of Xeris Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tibet Mineral Development Co Ltd
SHE:000762
|
0.009x |
|
Birchcliff Energy Ltd.
TO:BIR
|
0.042x |
|
Wolverine World Wide Inc
NYSE:WWW
|
-0.192x |
|
Arlo Technologies
NYSE:ARLO
|
0.072x |
|
Yulon Finance Corp
TW:9941
|
0.082x |
|
Siam City Cement Public Company Limited
BK:SCCC
|
0.028x |
|
Metrics Master Income Trust
AU:MXT
|
0.036x |
|
Shenzhen Dynanonic Co Ltd
SHE:300769
|
-0.042x |
Annual Cash Flow Conversion Efficiency for Xeris Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Xeris Pharmaceuticals Inc from 2016 to 2025. Review XERS cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.69 Million | $28.63 Million | 2.091x | +67.46% |
| 2024-12-31 | $-29.61 Million | $-36.98 Million | 1.249x | -81.99% |
| 2023-12-31 | $-6.78 Million | $-47.02 Million | 6.934x | +404.50% |
| 2022-12-31 | $45.19 Million | $-102.89 Million | -2.277x | -126.98% |
| 2021-12-31 | $95.23 Million | $-95.53 Million | -1.003x | +82.02% |
| 2020-12-31 | $14.44 Million | $-80.56 Million | -5.580x | +22.80% |
| 2019-12-31 | $14.44 Million | $-104.35 Million | -7.228x | -868.48% |
| 2018-12-31 | $75.41 Million | $-56.28 Million | -0.746x | -275.00% |
| 2017-12-31 | $-57.83 Million | $-24.66 Million | 0.426x | -15.34% |
| 2016-12-31 | $-31.93 Million | $-16.09 Million | 0.504x | -- |
About Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related … Read more